How do we use this product
The longest Phase 3 result published so far covers 68 weeks
In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May
Reference He, Y., Mi, N., Cheng, Z., Xue, H., Han, J., Wang, H., Wang, H., Wu, J., Shi, X., Zhao, S., Duan, B., Zhu, Y., Zhou, Y., Li, F., Wang, X., Ling, H., Wang, S., Li, Q., Jiang, F.,
None of them followed the firms own standard operating procedure for investigating OOS results
